Protara Therapeutics announced its Q1 2026 financial results and business updates, highlighting plans to submit a Biologics License Application (BLA) for its cell therapy TARA-002 in lymphatic malformations (LMs) in the second half of 2027. The company reported $177 million in cash and equivalents, supporting operations into 2028, and continues clinical trials for TARA-002 in both LMs and non-muscle invasive bladder cancer (NMIBC). Upcoming milestones include presenting updated trial data at major medical conferences and initiating new trials in the second half of 2026. The company also advances its IV Choline Chloride program for patients on parenteral support, expecting interim results later this year.
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...
